| HF | Heart Failure |
| HFrEF | Heart Failure with Reduced Ejection Fraction |
| HFpEF | Heart Failure with Preserved Ejection Fraction |
| HFmrEF | Heart Failure with Mildly Reduced Ejection Fraction |
| SGLT2 | Sodium-Glucose Cotransporter-2 |
| T2DM | Type 2 Diabetes Mellitus |
| NT-proBNP | N-terminal pro-B-type Natriuretic Peptide |
| eGFR | Estimated Glomerular Filtration Rate |
| KCCQ | Kansas City Cardiomyopathy Questionnaire |
| 6MWD | 6-Minute Walk Distance |
| RAASi | Renin–Angiotensin–Aldosterone System Inhibitor |
| MRA | Mineralocorticoid Receptor Antagonist |
| ARNI | Angiotensin Receptor–Neprilysin Inhibitor |
| AHF | Acute Heart Failure |
| MI | Myocardial Infarction |
| LV | Left Ventricle |
| LVEF | Left Ventricular Ejection Fraction |
| QALY | Quality-Adjusted Life Year |
| ICER | Incremental Cost-Effectiveness Ratio |
| NYHA | New York Heart Association |
| GDMT | Guideline-Directed Medical Therapy |
| euDKA | Euglycemic Diabetic Ketoacidosis |
| UTI | Urinary Tract Infection |
| nsMRA | Nonsteroidal Mineralocorticoid Receptor Antagonist |